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2352-3042/Copyright ª 2014, ChongqAbstract LKB1 is commonly thought of as a tumor suppressor gene because its hereditary mu-
tation is responsible for a cancer syndrome, and somatic inactivation of LKB1 is found in non-
small cell lung cancer, melanoma, and cervical cancers. However, unlike other tumor suppres-
sors whose main function is to either suppress cell proliferation or promote cell death, one of
the functions of LKB1-regulated AMPK signaling is to suppress cell proliferation in order to pro-
mote cell survival under energetic stress conditions. This unique, pro-survival function of LKB1
has led to the discovery of reagents, such as phenformin, that specifically exploit the vulner-
ability of LKB1-null cells in their defect in sensing energetic stress. Such targeted agents repre-
sent a novel treatment strategy because they induce cell killing when LKB1 is absent. This
review article summarizes various vulnerabilities of LKB1-mutant cells that have been reported
in the literature and discusses the potential of using existing or developing novel reagents to
target cancer cells with defective LKB1.
Copyright ª 2014, Chongqing Medical University. Production and hosting by Elsevier B.V. All
rights reserved.Introduction
The current cancer treatment paradigm is to inhibit bio-
logical pathways that are hyperactive in cancer cells withs of Hematology and Medical
Medicine, 1365 Clifton Road,
ia. Tel.: þ995 404 778 2134;
u (W. Zhou).
ity of Chongqing Medical
014.06.002
ing Medical University. Productionpharmaceutical reagents. While these approaches have
proven successful in the clinic, they share two common
limitations. First, the targeted proteins or pathways are
likely to play important physiological roles in some normal
tissues, and their inhibition thus leads to toxic side effects.
Second, cancer cells have defective DNA damage/repair
checkpoint(s) which make them genetically unstable.1
Consequently, cancer cells are genetically heterogeneous,
and each cell contains numerous pre-existing mutations
that are not normally selected. Systemic therapy creates an
environment for the selection of cancer cells with mutated
target proteins that no longer interact with the drug.
Therefore, side effects and secondary mutation-relatedand hosting by Elsevier B.V. All rights reserved.
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Therapeutic opportunities in LKB1-inactivated tumors 65drug-resistance are two inevitable consequences of current
cancer treatment approaches.
Tumor suppressor genes are not normally perceived as
viable drug targets, and a common quote from pharma-
ceutical companies is “how can you target something that is
not there?” It is important to note that even though Dr.
Frank McCormick pioneered the concept of killing p53-null
cells with the ONYX virus, the most successful clinical study
of this virus was accompanied by evidence that ONYX-015
kills cancer cells through a mechanism that is not related to
p53 inactivation.2,3 Recent studies have indicated that de-
fects in the LKB1-AMPK signaling pathway make tumors
vulnerable to varieties of stress, which can be exploited
therapeutically.
Liver kinase 1 (LKB1 also known as STK11) is a tumor
suppressor gene that is inactivated by bi-allelic mutation in
non-small cell lung cancer (NSCLC), malignant melanoma
and cervical cancer.4e6 Our knowledge of the biological
roles of LKB1 has rapidly expanded over the past decade.
Initial research focused on its roles in cell polarity, cell
motility, protein translation and energy metabolism, and
recent advances indicated that LKB1 is also involved in the
regulation of other cellular process, such as DNA damage
checkpoint, liposome function, and various signal trans-
duction pathways. Hence, the inactivation of LKB1 in
human tumors will lead to the de-regulation of multiple
cellular processes, but it is still unclear which of them is
related to tumorigenesis. From a treatment perspective,
the lack of proper regulation should make cancer cells
vulnerable to reagents that specifically inhibit these path-
ways. A therapeutic approach that can specifically elimi-
nate LKB1-deficient cells will have at least two advantages.
First, LKB1 is ubiquitously expressed in all tissue types, and
therapeutic approaches against LKB1-null cells should have
less toxic effects on normal tissues (i.e. fewer side ef-
fects). Second, LKB1 is frequently inactivated by bi-allelic
genetic inactivation. Because the genetic codes for LKB1
are lost in these cancer cells, they are unlikely to be
restored by genetic instability. Even if cancer cells find
another way to restore LKB1 function, its tumor suppressor
function should inhibit the growth of these cells. This re-
view article will focus on the nature of these vulnerabilities
and recent advances in the development of clinical re-
agents that target these vulnerabilities in LKB1-null cancer
cells (Table 1).T
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mLKB1 as a serine/threonine kinase
LKB1 protein has a central kinase domain, two N-terminal
nuclear leading sequences, and a C-terminal regulatory
motif. The protein also contains a CAAX motif at C-ter-
minal end and can be farnesylated. The formation of an
LKB1/Strad/MO25 complex is essential for LKB1’s kinase
activity,7 and there are at least 13 known substrates of
LKB1, which includes AMPKs, BRSKs, and MARKs.8 LKB1 is
ubiquitously expressed in all tissues, so the mere presence
of this protein does not inhibit cell proliferation.9 Existing
data indicate that LKB1 kinase activity can be regulated
either by post-translational modification of LKB1 itself or
by the regulation of conformational configuration of its
downstream targets. The upstream regulators of LKB1
Table 1 (continued )
Class Agents Targets / Mechanisms
that are LKB1 independent
Stage of development Comments Refs
AZD8055 ATP competitive inhibitor for
both mTORC1 and mTORC2
Phase 1 but not specifically
for LKB1 mutants
Preferentially
reduced both LDH
and PDH levels in
a STK11//NIC
breast cancer
model
81
BAPN LOX Laboratory 82
FAK/Src inhibitor PF573228 FAK inhibition in LKB1-null
background53
Laboratory 52,53
FAK/Src inhibitor
CHK1 inhibitors
Defactinib
(PF-4554878, VS-6063)
FAK inhibition Phase 1 & 2 including a trial
for KRAS mutant NSCLC, but
not specific for LKB1
Needs more
studies for
LKB1 mutants
52
Dasatinib Src inhibition Phase 1 & 2 for various
malignancies. Not LKB1 specific
52
AZD7762 CHK1 inhibition Phase 1 (solid tumor). Not
LKB1 specific.
Cardiac
toxicity83,
neutropenia84
54
CHK1 inhibitors
Nucleotide
metabolism inhibitors
CHIR124 CHK1 inhibition Laboratory 54
DTYMK shRNA DTYMK inhibition, reduce dTTP
biosynthesis
Laboratory 54
COPI/lysosomal
maturation inhibitors
Bafilomycin A1 (bafA) Inhibits vacuolar ATPase Laboratory 66
COPI/lysosomal
maturation inhibitors
YAP inhibitors/
Hippo activators
Saliphenylhalamide
A (saliPhe)
Inhibits vacuolar ATPase Laboratory 66
Dox-inducible YAP
shRNA (iYAP shRNA)
Silences YAP Laboratory 72,73
Verteporfin Disrupts the TEAD-YAP
interaction
Laboratory Suppresses YAP,
but needs to be
tested in the
setting of LKB1
mutation
74
Super-TDU Compete with YAP for the
interaction with TEAD
Laboratory Suppressed YAP
and gastric
cancer growth.
Needs to be
tested in LKB1
mutants
75
Only LKB1 independent targets and mechanisms are listed. The information of clinical trials was obtained from www.clinicaltrials.gov. Although some of the listed agents have already
been enrolled in clinical trials, only very few of them were specifically designed for LKB1 mutants. Also, some of the listed agents are still in silencing RNA formula, but due to their
potentiality and good mechanistic studies, they are included here as well.
Abbreviations: AICAR: 5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside; DTYMK: deoxythymidylate kinase; LOX: lysyl oxidase; BAPN: b-aminopropionitrile; PJS: PeutzeJeghers
Syndrome; LDH: lactate dehydrogenase; PDH: pyruvate dehydrogenase; NIC: Neu/HER2-MMTV-Cre.
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Therapeutic opportunities in LKB1-inactivated tumors 67include ERK, RSK, ATM, and DNA-PK, most of which will be
discussed in this review.Mechanism of LKB1 inactivation in human tumors
Genetic inactivation of LKB1
LKB1 was first found to be associated with PeutzeJeghers
syndrome.10 This is an autosomal dominant disease that is
characterized by gastrointestinal hamartomatous polyps,
and elevated risk of various neoplasms.11 Many patients
carry germline mutations that inactivate the kinase func-
tion of LKB1.12 This finding initiated intensive surveys for
somatic LKB1 mutation analysis in human tumors, and LKB1
was subsequently found to be frequently mutated in non-
small cell lung cancer (NSCLC), melanoma, and cervical
cancers.4e6 The mutation frequency of LKB1 in NSCLC is still
undetermined. Initial analysis in lung cancer cell lines
indicated that LKB1 is inactivated in 30% of samples,4 but
sub-sequence analysis in adenocarcinomas only revealed
5e15% point mutations. Part of this confusion is due to the
fact that LKB1 is frequently inactivated by homozygous
deletion which will not be detected by sequencing analysis
alone. A combined analysis of homozygous deletion and
LOH with somatic mutation indicated LKB1 is inactivated in
39% of NSCLC samples.13 Similarly, a combined sequencing
and LKB1-large deletion analysis revealed 27% of Chinese
lung adenocarcinomas contain LKB1 genetic alteration.14
The NextGen sequencing method should provide data on
both somatic mutation and copy-number variations, and
such analysis in the future should be able to provide a
definitive number on LKB1 mutation frequencies in these
tumor types.
LKB1 mutation was found to be rare in most other tumor
types, which suggests that the deletion of LKB1 can only
provide a growth advantage in certain tumor types. In the
case of lung cancers, LKB1 mutation is limited to NSCLC.
Adenocarcinoma of the lung contains the highest mutation
frequency of LKB1, and LKB1 was also found to be mutated
at lower frequencies in large cell and squamous cancer of
the lung.15,16 Interestingly, a recent study in a mouse model
shows that Lkb1-deficient lung adenocarcinoma (ADC) pro-
gressively transdifferentiates into squamous cell carcinoma
(SCC) through pathologically mixed ADCeSCC in-
termediates.17 This finding immediately raised the
following questions: (i) does human LKB1-mutant SCC also
transdifferentiate from ADC, (ii) if so, does this trans-
differentiation provides an advantage for tumor survival in
the lung tissue microenvironment, and (iii) do human LKB1-
mutant ADC and SCC have differential drug responses?
Addressing the third question may have significant impli-
cations for the treatment approach to LKB1-mutated
squamous lung cancer.
Epigenetic inactivation of LKB1
Although LKB1 is bona fide tumor suppressor gene, the lack
of somatic LKB1 mutations in other major cancer types was
puzzling. This led to the investigation of whether LKB1 can
be inactivated in other cancer types through epigenetic
modification. Initial analysis in 51 cancer cell lines indi-
cated that three colorectal and one cervical carcinoma cell
lines contain LKB1 promoter methylation. Similar analysisin 195 carcinomas of various tissue types revealed alter-
ations in one colorectal carcinoma and three testicular
carcinomas.18 The low frequency of LKB1 promoter
methylation was also confirmed in colorectal cancer, he-
patocellular carcinoma, and astrocytoma.19e21 The only
exception reported is a recent study by a Korean group who
found LKB1 promoter methylation in 13% of samples, and
argued that LKB1 genetic and epigenetic alteration may
vary depending on patient ethnicity.22 In general, LKB1 is
not frequently inactivated in human cancers by epigenetic
modification.
Biological inactivation of LKB1
Even though the epigenetic inactivation of LKB1 is a rare
event in human cancer, a recent development is the dis-
covery that the phosphorylation of AMPK by LKB1 is
attenuated in melanoma cells with BRAF V600E activating
mutation.23,24 Mechanistically, the presence of BRAF
V600E mutation activates MEK/ERK signaling and its
downstream target RSK. The phosphorylation of LKB1 at
Ser325 and Ser428 by ERK2 and p90RSK was shown to be
sufficient to inactivate LKB1 as an energy sensor through
the disruption of LKB1’s interaction with its downstream
effect molecule AMPK.23 Interestingly, LKB1’s interaction
with Strad and MO25 was not affected in this specific
scenario, and it is unknown whether LKB1 is still capable
of interacting with its other downstream targets in the
presence of BRAF V600E mutation. In any case, this
example begs the question whether LKB1 can interact
with other cellular components, and whether similar types
of protein-protein interactions are also capable of inhib-
iting LKB1 kinase function. If these types of inhibitory
proteins are present in other tumor types, targeted ap-
proaches against LKB1-deficient tumors may also be
applicable in these tumors.The unanticipated use of AMPK activators against
LKB1-null tumor cells
Metformin, phenformin and AICAR are commonly used as
AMPK activators even though their mechanisms of activa-
tion are different. Metformin and phenformin treatments
inhibit mitochondria complex I,25e27 which can lead to the
depletion of intracellular ATP and a rise in AMP. The binding
of AMP to g-regulator domain promotes the phosphorylation
of AMPK at threonine 172 by upstream kinases, such as
LKB1.28 This binding also protects the enzyme against
dephosphorylation by phosphatases and causes allosteric
activation of AMPK.29 LKB1 is also required in the process of
AMPK activation because the farnesylation of LKB1 was
recently found to be required for the activation of AMPK by
phenformin.30
Extensive experimental data indicates that the activa-
tion of AMPK by metformin or phenformin has anti-
proliferative activity in many cancer types, but the un-
derlying mechanisms are not completely understood.31
mTOR is one of the downstream targets that is inhibited
by AMPK, which leads to inhibition of protein synthesis and
cell proliferation.32 Another hypothesis is that tumor cells
have defects in various aspects of lipid metabolism, and
they are dependent on de-regulated lipid metabolism. The
68 W. Zhou et al.activation of AMPK is capable of inhibiting lipid metabolism,
thus suppressing cell proliferation.33 In summary, current
data indicate that AMPK-dependent growth inhibition by
metformin and phenformin in human cancers is LKB1-
dependent.
An unexpected finding from studies of metformin and
phenformin is that treatment of LKB1-null cells with these
reagents leads to cell death.27 AMPK is not a mediator in
this process because activated AMPK cannot be detected
after such treatment. Therefore, LKB1-dependent AMPK
activation is not the cause of this apoptosis. It should be
noted that the inhibition of mitochondria complex I and the
depletion of intracellular ATP by metformin and phenfor-
min are LKB1-independent, so these reagents generate
energetic stress regardless of LKB1 status. The mechanism
underlying phenformin-induced cell death in LKB1-null cells
was recently proposed.27 It was hypothesized that
phenformin-induced ATP depletion is usually detected by
the LKB1/AMPK metabolic checkpoint, whose activation re-
balances the energy consumption in cancer cells to pro-
mote cell survival. However, LKB1-null cells cannot sense
this defect, and the lack of proper energy consumption
control eventually leads to cell death (Fig. 1). This hy-
pothesis suggests that LKB1/AMPK plays a pro-survival role
against phenformin-induced cell killing.
5-Aminoimidazole-4-carboxamide riboside (AICAR) is
another commonly used AMPK activator. Inside a cell, AICAR
is converted to AICAr monophosphate (ZMP) by adenosine
kinase, and ZMP can act as an AMP analog to activate AMPK
in an LKB1-dependent manner. Interestingly, the introduc-
tion of AICAR also induces caspase-3 cleavage in LKB1-null
MEF cells and ovarian cancer cells,34,35 although the un-
derlying mechanism(s) have not been explored. Even
though AICAR-induced activation of AMPK has been shownFigure 1 The effects of AMPK activators in LKB1-wild type and
complex I, which results in the depletion of intracellular ATP and in
kinase activity and its metabolic regulation function. The lack o
metformin and phenformin induced energetic stress cannot be pro
cell death.to promote apoptosis in many cell lines, this type of
apoptosis is usually dependent on the activation of
AMPK.36,37 This is unlikely to be the mechanism in LKB1-null
cells because genetic evidence shows that AMPK activation
in response to treatment with AICAR is compromised in
LKB1-/-MEFs, and can be restored following reconstitution
of LKB1.38,39 Depending on the cell type, the introduction
of AICAR may or may not lead to the depletion of ATP.40,41
Hence, it will be interesting to see in the future whether
AICAR induces apoptosis in LKB1-null cells through a
different mechanism, and whether LKB1/AMPK also pro-
vides a pro-survival role for cancer cells in this treatment
setting.Hyper-activated mTOR and ribosomal RNA synthesis
in LKB1-null cells
mTOR is one of the earliest signaling pathways that was
found to be negatively regulated by LKB1/AMPK signaling.
Extensive experimental evidence indicates that mTOR-
mediated protein translation is hyper-activated in cancer
cells without LKB1, and various rapamycin analogs (rapa-
logs) have been developed to suppress the activity of
mTORC1 (Fig. 2). This topic has been extensively reviewed
elsewhere.32,42,43 Currently, these rapalogs (everolimus,
sirolimus, temsirolimus) are in multiple phase 1-3 clinical
trials, and NCT00178151 is a phase 2 trial that specifically
evaluate the effects of everolimus in the treatment of
advanced malignancies in patients with PeutzeJeghers
syndrome. Even though mTOR inhibitors have shown activ-
ities in some lung cancer patients, the underlying mecha-
nism is still unknown. In a genetically engineered mouse
model, invasive endometrial tumors derived frommutant cells. Metformin and phenformin inhibit mitochondria
creases in AMP. The binding of AMP to the AMPK activates AMPK
f LKB1 prevents the activation of AMPK by AMP. As a result,
perly detected in LKB1-mutant cells, which eventually lead to
Figure 2 AMPK regulates protein translation through its ef-
fects on mTOR and pre-rRNA synthesis. The activation of AMPK
suppresses mTOR activity, thus interfering with translation
initiation. AMPK also phosphorylates TIF-IA to prevent the as-
sembly of pre-rRNA transcription initiation complex, thus
prevent the synthesis of ribosome which is required for protein
translation.
Therapeutic opportunities in LKB1-inactivated tumors 69concurrent loss of Pten and LKB1 rely strongly on dysregu-
lated mTOR signaling, and are hypersensitive to mTOR in-
hibition.44 Interestingly, the concurrent loss of Lkb1 and
Pten also leads to mouse lung SCC that recapitulates the
human disease,45 and it will be interesting to determine in
the future whether mTOR inhibitors are specifically useful
in patients with both LKB1 and PTEN mutations.
Another important component of protein synthesis is the
ribosome. The transcription of ribosomal RNA (rRNA) genes
by RNA polymerase I and the subsequent maturation pro-
cessing of rRNA are essential steps in the generation of
functional ribosomes. Several hereditary cancer syn-
dromes, such as Blooms syndrome, Werner syndrome, and
ShwachmaneDiamond syndrome, have defects either in
rDNA transcription or rRNA processing.46 In addition, hy-
peractive Pol I transcription was recently shown to be
required for maintaining the malignant phenotype of B-
lymphoma.47 The recruitment of TIF-IA/Pol-I complex to
the rRNA promoter is essential for the formation of the
rRNA transcription initiation complex.48 Emerging evidence
indicates that AMPK is also involved in the regulation of pre-
ribosomal RNA synthesis (Fig. 2). First, mTOR phosphory-
lation of TIF-IA at Ser-44 activates and at Ser-199 in-
activates rRNA transcription.49 Because AMPK negatively
regulates mTOR, this is the first indirect evidence that
AMPK is involved in the regulation of rRNA transcription.
More recently, AMPK was found to directly phosphorylate
TIF-IA at Ser-635, which disrupts the interaction of TIF-IA
with transcription factor SL1 and prevents the assemblyof the transcriptional initiation complex.50 This evidence
indicated that AMPK is also a negative regulator of pre-rRNA
synthesis. Hence, AMPK may negatively regulate protein
synthesis through the inhibition of both mTOR and ribosome
synthesis. Currently, it is unknown whether the negative
regulation of pre-rRNA synthesis by AMPK is LKB1-
dependent. If this is the case, reagents that inhibit rRNA
transcription or rRNA maturation may also be used against
LKB1-null cancers.
Sensitivity to Fak/Src inhibitors
The role of LKB1 in regulating lung cancer invasion and
metastasis is an emerging research field. Early studies in
Drosophila indicated that LKB1 is involved in regulation of
cell polarity, and the loss of epithelial polarity may be
related to epithelial to mesenchymal transition (EMT).51
Direct evidence of LKB1’s involvement in cancer metas-
tasis came from a study in a mutant Kras mouse model, in
which the additional loss of Lkb1 accelerated tumor pro-
gression and promoted metastasis.16 This was a ground-
breaking study because it provided in vivo evidence that
the inactivation of LKB1 not only disrupts the regulation of
mTOR signaling but also promotes cancer metastasis. A
follow-up analysis in this mouse model indicated that SRC
and FAK are activated in Lkb1-deficient primary and met-
astatic lung tumors.52 The negative correlation between
LKB1 and FAK activation was also reported in human cancer
cell lines where LKB1 was found to suppress FAK activity.53
These findings suggest that LKB1-null cancer cells may have
hyper-activated SRC/FAK function, thus rendering them
susceptible to SRC/FAK inhibition. Dasatinib is a Src inhib-
itor that is already in phase 1 and 2 clinical trials for various
malignancies. Defactinib is a FAK inhibitor that is also in
phase 1 and 2 clinical trials, one of which is a trial for Kras-
mutant NSCLC patients. It will be interesting to see in the
future whether these reagents can prevent the metastasis
of LKB1-mutant tumors by targeting FAK or Src.
LKB1 as a sensor for DNA damage
A recent synthetic lethality screen revealed that the
downregulation of DTYMK and Chk1 expression by RNAi
preferentially induced cell killing in LKB1-null cells, and
that LKB1-null cells accumulated more DNA damage than
their isogenic LKB1-wild type counterparts.54 This finding
suggested that LKB1 may play a role as a sensor for DNA
damage, and that LKB1-mutant cells are defective in this
DNA damage checkpoint. Consequently, these cells rely on
Chk1’s function as the last defense against DNA damage,
making Chk1 depletion a synthetic lethal combination with
LKB1.
The puzzle here is how LKB1 acts as a sensor for DNA
damage (Fig. 3). The most obvious question is whether
nuclear LKB1 plays a role in this process. LKB1 has two
nuclear leading sequences and LKB1 expression is present in
the nucleus. Furthermore, decreased nuclear LKB1 levels
correlate with HNSCC metastasis, suggesting that nuclear
LKB1 is capable of suppressing HNSCC.55 A similar phe-
nomenon was found in breast cancer, where the presence
of nuclear LKB1 is associated with increased overall survival
Figure 3 The role of LKB1 as a ROS sensor but not a genomic
stress sensor. Ionization radiation activates ATM and AMPK in a
LKB1-independent manner to sense genomic stress. LKB1/
AMPK is required for reactive oxygen species (ROS) to activate
mTOR through cytosolic ATM.
70 W. Zhou et al.and disease-free survival.56 Despite these interesting cor-
relations, the nuclear function of LKB1 is still unknown.
First, there is no direct evidence indicating that LKB1
can function as a kinase in the nucleus. The kinase function
of LKB1 is mainly limited to the cytosol as the LKB1/STRAD/
MO25 complex is mostly found in the cytosol. Even though
STRADa is capable of passive diffusion into the nucleus, its
main function appears to be to re-localize LKB1 into the
cytosol.57 Second, even though AMPK was recently pro-
posed as a sensor for genomic stress,58 the phosphorylation
of AMPK after ionizing radiation (IR) in the nucleus is mostly
mediated by ATM and ATR59,60 and is observed in both LKB1-
wild type and mutant cell lines.59 Therefore, ionization-
mediated AMPK response in the nucleus appears to be
LKB1-independent. These findings, however, do not
necessarily rule out LKB1 as a sensor for genetic damage
because the N-terminus of ATM does interact with LKB1,61
and ATM is capable of phosphorylating LKB1 at Thr-366.62
Interestingly, recent data indicated that ATM negatively
regulates mTORC1 and induces autophagy via the LKB1/
AMPK pathway in the cytoplasm,63 and cytoplasmic ATM is
capable of activating LKB1/AMPK in response to reactive
oxygen species (ROS).64 These data provided evidence that
ATM and LKB1 may function as a sensor for oxidative stress
in the cytosol. Because ROS is an important source of
oxidative DNA damage,65 LKB1 may indirectly act as a
sensor to control oxidative DNA damage. Consequently,
reagents against DNA damage checkpoint proteins may be
valuable for the treatment of LKB1-mutant cancer in the
future.
Kras-LKB1 mutation-driven COPI addition
A recent study discovered that cancer cell lines with com-
bined mutations in Kras and LKB1 are particularly sensitive
to the depletion of coatomer complex I (COPI) subunits,
such as ARCN1, COPB1 and COPA.66 These data suggest that
Kras/LKB1 mutant cell lines are addicted to some functions
mediated by COPI. COPI is involved in various membrane-
trafficking events, and is best known for its role incoating vessles to be returned to the ER after they reach
the cis or ER-Golgi intermediate compartment, a.k.a.
retrograde transport.67 However, the authors presented
evidence that Kras/LKB1 mutant cells are addicted to
COPI’s role in lysosome acidification. Lysosomes are cellular
vesicles containing many different acid hydrolases, which
are capable of degrading various biomolecules, including
proteins, carbohydrates, lipids, and nucleic acid. The
acidification of lysosomes is an important step in their
maturation process because many lysosomal enzyme pre-
cursors can only be properly cleaved into their mature form
at acidic pH, and most lysosomal hydrolases are active only
at acidic pH. In addition, the acidity also denatures proteins
to make them easier to digest. Kras/LKB1-null cells were
found to have more acidic lysosomes in their steady-state
organelle accumulation. Therefore, these cells may be
selectively dependent upon lysosomal maturation. Consis-
tent with this, the vacuolar ATPase inhibitor bafilomycin A1
and saliphenylhalamide A were found to have selective
toxicity against Kras/LKB1-mutant cell lines. Even though
these reagents have only been tested in the laboratory
setting, future development of clinical grade vacuolar
ATPase inhibitors may have important implications in the
treatment of Kras/LKB1 mutant lung cancers.Hyper-activated YAP1 as a therapeutic target in
LKB1-mutant cancers
The Hippo pathway is an ancient developmental pathway
that regulates organ size and proliferation. It inhibits cell
proliferation upon high cell density or stress, and can act as
a tumor suppressor pathway in many tissues. One of the
main downstream targets that is suppressed by the Hippo
pathway is YAP1 (Yes-associated protein 1), a transcription
co-activator that associates with the TEAD family of tran-
scription factors to promote cell proliferation.68 In some
cancers, such as melanoma, YAP1 is amplified to act as an
oncogene.69 YAP1 has not been reported to be amplified in
lung cancer, but elevated nuclear YAP1 expression has been
observed and it negatively correlates with patient survival
and LKB1 expression.70e73 In addition, RNAi knockdown of
LKB1 significantly enhanced the transcription of YAP1-
activated genes, and the over-expression of LKB1 inhibits
YAP1-dependent transcription. Interestingly, YAP1 has also
been shown functionally essential since the depletion of
YAP1 reduced the growth of LKB1 mutant tumors, and its
mutant form (YAP-S217A) was able to significantly over-
come all of LKB1’s tumor suppressive effects.73 LKB1 is a
serine/threonine kinase. Even though LKB1 does not
directly interact with YAP1, the over-expression of LKB1
correlates with an increase in the phosphorylation of YAP1
at Serine 127 and the degradation of YAP1 by the protea-
some.72 RNAi analysis indicated that three LKB1 substrates
(MARK1, 3 and 4) are capable of modulating YAP1-
dependent transcription, and protein-protein interaction
studies suggested that LKB1, MARK, MST1, LATS1 and SCRIB
may form a Hippo regulator protein complex.73 Therefore,
LKB1 is a suppressor of YAP1 function, and aberrant acti-
vation of YAP1 function may be another biological basis for
the mutational inactivation of LKB1 in lung cancer. Because
YAP1 is hyper-activated and is functionally essential in
Therapeutic opportunities in LKB1-inactivated tumors 71LKB1-mutant cells, therapeutic strategies against YAP1
activation may be beneficial in the treatment of LKB1-
mutant tumors (Fig. 4). Existing strategies include (i) the
delivery of shRNA against YAP1, (ii) reagents that disrupt
the YAP1/TEAD interaction (verteporfin),74 and (iii) re-
agents that compete with YAP for its interaction with STEAD
(Super-TDU).75 These reagents are currently in pre-clinical
development but they certainly represent an appealing
strategy to eliminate LKB1-mutant cancers.
Vulnerability of LKB1-mutant cells to Hsp90
inhibitor, 17-AAG
The Genomics of Drug Sensitivity in Cancer (GDSC) recently
published drug sensitivity data on 138 anticancer drugs in
approximately 700 cancer cell lines,76 and LKB1-mutant
cancer cell lines were found to be most sensitive to 17-
AAG (http://www.cancerrxgene.org/translation/Gene/
1367). 17-AAG (17-N-allylamino-17-demethoxygeldana
mycin) is a derivative of geldanamyin, which was initially
used to reveal a protein-protein interaction between LKB1
and Hsp90.77,78 Initially, Hsp90 and Cdc37 were found to
bind specifically to the kinase domain of LKB1, and prevent
ubiquitin-mediated LKB1 degradation by the protea-
some.77,78 More recent data indicated that LKB1 in complex
with Hsp90/Cdc37 has a longer half-life but lacks its auto-
phosphorylation.79 Its kinase activity, however, can be
transiently stimulated when it is released from Hsp90/Figure 4 LKB1 negatively regulates YAP1 function. LKB1
regulates SCRIB cellular localization through its phosphoryla-
tion of MARK. The proper cellular localization of SCRIB is
required for the regulation of YAP phosphorylation by its up-
stream kinases, such as MST and LATS.Cdc37.79,80 The released LKB1 interacts with Hsp/Hsc70,
which recruits the ubiquitin ligase CHIP to mark LKB1 for
proteasome-mediated degradation.79 A G163D point muta-
tion in LKB1 was previously found to weaken the interaction
between Hsp90/Cdc37,77 but it is unclear whether the
weakened LKB1/Hsp90/Cdc37 interaction is responsible for
the increased cancer cell sensitivity to 17-AAG. Further-
more, most LKB1-mutant cancer cell lines contain nonsense
or frameshift mutations that usually abolish the production
of LKB1 protein. Once again, LKB1 appears to play an un-
known protective role in cancer cells against the toxicity of
17-AAG, and additional research is required to delineate
the molecular basis for 17-AAG sensitivity of LKB1 mutant
tumors.
On a side note, GDSC screen also included many thera-
peutic reagents currently used for the treatment of human
cancers, such as paclitaxel, docetaxel, cisplatin, etc. None
of these reagents have a growth inhibitory bias against
LKB1-mutant cancer cell lines at statistical significant level.
Hence, there is no direct evidence at this time for a se-
lective or preferential reduction of LKB1-mutant cells by
conventional cancer therapy, further supporting the needs
in developing novel therapeutic reagents against LKB1-
mutant tumors.Conclusions
Therapeutic strategies against LKB1-mutant cancer are
emerging, and their discovery can be classified into three
categories. The first group is based on the biological func-
tion of LKB1 in regulating other signaling pathways. LKB1
was found to negatively regulate the activities of mTOR,
FAK/Src, and YAP1, and LKB1-mutant cells may become
dependent on the hyper-activation of these signaling
pathways. Hence, inhibitory reagents against the function
of these proteins should be useful for the treatment of
LKB1-mutant cells. However, these reagents are not spe-
cifically designed against LKB1-mutant cells because these
pathways may be aberrantly activated by mutations in
other genes. The second group is based on unbiased syn-
thetic lethality screening, and targeted inhibitions of pro-
teins, such as Dtymk and Chk1, preferentially induces the
killing of LKB1-null cells. The third group is associated with
the function of LKB1 as a sensor for varieties of environ-
ment stresses, and cells with defective LKB1 appear unfit to
detect such environmental insults. An interesting challenge
in the future is to identify reagents, whose incorporation
into the DNA, RNA or proteins will be detrimental for cell
survival but can not be properly detected in LKB1-null cells.
Such approach may lead to the development of unorthodox
agents against LKB1-mutant cells which is not based on the
inhibition of any proteins. It should be noted that these
strategies may not be limited to cancer cells with LKB1
mutations because LKB1 can also be inactivated at the
protein level by other proteins.Conflict of interest
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